Body examination of breast hyperplasia, was diagnosed with breast cancer a month later. Ms. Wang of Ningbo wondered why the physical examination could not be checked out. At present, the rate of early missed diagnosis of breast cancer is as high as 70% or more, which is difficult to detect by routine physical examination.
In mid-July, the 47-year-old Ms. Wang (a pseudonym) organization organized a physical examination at a private medical examination center to check out hyperplasia of the breast. One month later, she touched a lump on the right breast and went to the Second Hospital of Ningbo to confirm breast cancer. Ms. Wang wondered why the physical examination could not be checked out.
In fact, the breast scan is a routine physical examination project, and it is mainly checked in advance whether the breast has lesions. Non-professional breast examinations mostly use the two old methods of breast clinical examination and infrared breast scan, leading to the early missed diagnosis rate of breast cancer as high as 70%%.
The formal breast examination includes three items: clinical examination, B ultrasound, and high-resolution digital molybdenum target. 40 to 50 years old is a high-risk age group for breast cancer. Screening for breast cancer cannot rely on general health check-ups. It must go to a regular medical institution. A full set of regular checkups such as clinical examinations for breast specialists, mammography, and ultrasound examinations are used. Can accurately find early breast cancer. The simultaneous application of the three major methods, the chance of missed diagnosis in clinical practice is quite small, of course, do not rule out the very early lesions, breast MRI examination of the Breast Department of the Second Hospital of Ningbo will be able to send a big use.
In short, what are the key issues in breast health care? It is not a health care product, not a massage in a beauty salon, but a good medical examination habit and concept. It is disease-free, disease-preventable, and disease-free.
Palbociclib is a drug for the treatment of ER-positive and HER2-negative breast cancer developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
It was reviewed and approved under the Food and Drug Administration`s (FDA) accelerated Priority Review and Breakthrough Therapy designation programs on February 3, 2015 as a treatment (in combination with letrozole) for patients with estrogen receptor positive advanced breast cancer.
We produce a series of complete intermediates for Palbociclib, intermediate I (CAS No. 571188-59-5), intermediate II (CAS No. 1013916-37-4) and intermediate III (CAS No. 1016636-76-2) etc.
All of our products are with stable production and strict quality control, making sure your experience with Sunshine Biotech is always enriching, satisfying and fulfilling.
Palbociclib Intermediates,Cas 571188-59-5,Cas 1013916-37-4,Cas 1016636-76-2
Nanjing Sunshine Biotech Co., Ltd , https://www.sunshine-bio.com